The second edition of Immunotherapy is an updated overview of immuno-oncology in acute myleloid leukemia, non-small cell lung cancer and sarcomas, showcasing advances in the management of cancer broadly classified as hematological malignancies, solid tumors and tumors arising in the connective tissue. Scientists, oncologists and advanced students will be provided with knowledge of basic immunology in the context of tumor biology, providing a comprehensive overview of the cellular components of the immune system that interact with each other to provide a successful immune response. A number of new, scientific findings in his fast moving field have necessitated a thoroughly updated and revised edition including the use of immunotherapy for gastrointestinal and genitourinary cancers, as well as discussions on optimizing radiotherapy with immunotherapeutic approaches, biomarkers of response or resistance to immunotherapy, cancer imaging in immunotherapy, skin reactions to immune checkpoint inhibitors and more.

As immunotherapeutic agents differ significantly from chemotherapeutic agents in response patterns and toxicity profiles, evaluating their safety and efficacy in clinical trials remains a challenge. The new edition will discuss the use of a variety of traditional and new immunotherapy criteria to evaluate response, their inadequacies and clinical implications. Additionally, the book will outline how new advances in medical imaging technology has the potential to provide high-dimensional data to improve decision support and individualize treatment selection and monitoring.

Joud Hajjar is an Assistant Professor of Allergy and Immunology and serves as the service chief of adult allergy and immunology at Texas Children's Hospital. She is a member of the Basic and Clinical Immunology Interest group at the American Academy of Allergy Asthma and Immunology, and the Early Career Immunologist Committee at the Clinical Immunology Society.

Dr. Hajjar serves as a reviewer for the Journal of Clinical Immunology, Journal of General Internal Medicine and Allergy and Asthma Proceedings. She has received travel awards to present her research at the Clinical Immunology Society, American Academy of Allergy, Asthma and Immunology, and the American College of Allergy, Asthma and Immunology national meetings.

Dr. Hajjar's research interests are in primary immunodeficiency disorders, and cancer immunotherapy.